Sanofi makes $3.2B bet on mRNA by acquiring partner Translate Bio

In the rush to snatch up clinical assets based on messenger RNA, or mRNA, Sanofi (NYSE: SNY) is buying its longtime partner Translate Bio (Nasdaq: TBIO) in an all-cash transaction that values the firm at $3.2 billion.